Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.

Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...

Galderma's efforts to expand the market for Nemluvio are bearing more fruit. In Europe, officials approved the subcutaneous drug for the treatment of moderate-to-severe atopic dermatitis in ...

The following is a summary of “Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory ...

As everyone knows, scratching at chronically itchy skin only makes the problem worse. A new device is claimed to help stop ...